Featured Research

from universities, journals, and other organizations

Australian Company Reports Progress In Development Of Testosterone Lotion For Men

Date:
September 7, 2005
Source:
Research Australia
Summary:
Acrux Limited, the Australian pharmaceutical company which specialises in administering drugs through the skin, today announced positive results from two more clinical studies of its Testosterone MD-Lotion® treatment for testosterone deficiency in men.

Acrux Limited (ASX: ACR), the Australian pharmaceuticalcompany which specialises in administering drugs through the skin,today announced positive results from two more clinical studies of itsTestosterone MD-Lotion® treatment for testosterone deficiency in men,which is associated with a number of symptoms including lethargy,depression and reduced libido. Both studies were conducted at theCentre for Clinical Studies, Melbourne, with Professor Susan Davissupervising as Principal Investigator.

The studies compared bloodlevels of testosterone in healthy volunteers. The aim of the firststudy was to compare two different formulations of Testosterone MDLotion®, and the aim of the second study was to compare two differentapplication sites.

The results of the first study showed thatboth formulations provided similar blood levels, providing options forcontinued development of either formulation. In the second study, therewas a significant difference in absorption between the two differentapplication sites, providing important information for the design ofthe remaining clinical studies in men.

In both studies, thelotion was well tolerated, with no application site reactions noted,and no serious adverse events recorded. Full details of the studies arepresented in Appendix 1.

Acrux's development of Testosterone MDLotion® is continuing, with further studies to commence shortly toconfirm the doses required to maintain testosterone blood levels in thetarget range for effective treatment.

Acrux CEO and ManagingDirector, Dr Igor Gonda said: "We believe our fast drying, no-touchmetered dose lotion has significant competitive advantage over theexisting products in this growing market. The remaining trials suit ourexpertise and require moderate investment, so in line with ourfinancial plans we intend to complete them ourselves before choosingthe best option for sales and marketing".

The remaining development programme:
Thethree remaining clinical studies will involve measuring the amount ofdrug delivered to the bloodstream ("pharmacokinetics"), followingadvice from the US Food and Drug Administration (FDA). This means thatthe programme is more straightforward and has lower risk and lower costthan a traditional clinical study programme. Acrux plans to completeall remaining development, using its own expertise and experience inpharmacokinetic studies. A New Drug Application is targeted formid-2008 to obtain FDA approval to market the product in the USA. Thenext clinical study will commence later this year. This study willassess testosterone blood levels in male volunteers after multipledoses of Testosterone MD-Lotion®, with completion of the study plannedfor early 2006.

The target market:
It is estimated that fourto five million men suffer from low testosterone (hypogonadism) in theUSA alone, with this figure predicted to increase in future years.Global sales in the year to January 2005 of products to treathypogonadism were US $415 million, representing an increase of 12% overthe previous year (IMS Health, IMS Midas, MAT, Jan 2005).

###

About Acrux
www.acrux.com.auAcrux is a specialty pharmaceutical company, developing andcommercialising a range of patented, patient-preferred healthcareproducts for global markets, using its innovative technology toadminister drugs through the skin.

Acrux's product pipeline includes treatments of hormonaldeficiencies, pain and central nervous system disorders, as well as acontraceptive.

19 human clinical trials have been completed with 7 different drug products and the lead product, EvamistTM (Estradiol MDTS®), is currently in a phase 3 clinical trial in the USA.

Acrux has licensed USA rights for EvamistTM(Estradiol MDTS®) and Testosterone MDTS® to VIVUS and AUS/NZdistribution rights for Testosterone MDTS® and Fentanyl MDTS® to CSLLimited. Acrux has also licensed its technology to Eli Lilly forveterinary healthcare products, to Napa Biosciences for certaindermatology products and to Connetics for anti-psoriatics and localanaesthetics.


Story Source:

The above story is based on materials provided by Research Australia. Note: Materials may be edited for content and length.


Cite This Page:

Research Australia. "Australian Company Reports Progress In Development Of Testosterone Lotion For Men." ScienceDaily. ScienceDaily, 7 September 2005. <www.sciencedaily.com/releases/2005/09/050907100239.htm>.
Research Australia. (2005, September 7). Australian Company Reports Progress In Development Of Testosterone Lotion For Men. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/09/050907100239.htm
Research Australia. "Australian Company Reports Progress In Development Of Testosterone Lotion For Men." ScienceDaily. www.sciencedaily.com/releases/2005/09/050907100239.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins